Some images has been designed using resources from Unsplash & Pixabay & Pexels & Freepik and some icons from Flaticon
跳到主要內容
Search
:::

黃怡翔 (Yi-Hsiang Huang)

黃怡翔(Yi-Hsiang Huang)圖 Return Appointment First Appointment

[Profile]

  • Education
    • Ph.D., Institute of Clinical Medicine; National Yang-Ming University School of Medicine, Taipei, Taiwan,
    • M.D., National Yang-Ming University School of Medicine, Taipei, Taiwan,
  • Career and Experience
    Current Positions：
    • - Now, Attending Physician, Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan,
    • - Now, Professor, Institute of Clinical Medicine, National Yang-Ming University Chiao-Tung School of Medicine, Taipei, Taiwan,
    Experiences：
    • - , Post-doc fellow, Vaccine Branch, National Cancer Institute, National Institute of Health, Bethesda MD, USA,
    • - , Chief Resident, Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan,
    • - , Resident, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan,
  • Medical Expertise
    1. Chronic hepatitis B and C
    2. Liver cirrhosis and its complications
    3. Liver cancer treatment (Radiofrequency ablation and percutaneous ethanol injection therapy)
    4. Abdominal ultrasound and GI tract endoscopy
  • License
    Board-certified Physician, Diploma of Department of Health, Executive Yuan, Taiwan Board-certified Gastroenterologist and Instructor, Diploma of The Gastroenterological Society of Taiwan Board-certified Digestive Endoscopist and Instructor, Diploma of The Digestive Endoscopy Society of Taiwan

[Publications]

1. Lee PC, Wu CJ, Hung YW, Lee CJ, Chi CT, Lee IC, Yu-Lun K, Chou SH, Luo JC, Hou MC, Huang YH.*. Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitors-treated unresectable hepatocellular carcinoma. J Immunother Cancer 2022 Jun;10(6):e004779. (*corresponding author)

2. Chen MH*, Lee IC, Chen MH, Hou MC, Tsai CY, Huang YH*. Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease. Annals of Rheumatic Diseases 2021 Nov;80(11):1393–1399. (*corresponding author)

3. Lee IC, Huang JY, Chen TC, Yen CH, Chiu NC, Hwang HE, Huang JG, Liu CA, Chau GY, Lee RC, Hung YP, Chao Y, Ho SY*, Huang YH*. Evolutionary Learning Derived Clinical-Radiomic Models for Predicting Early Recurrence of Hepatocellular Carcinoma After Resection. Liver Cancer. 2021;10(6):572-582. (*corresponding author)

4.. Chen MH, Chen MH, Chou CT, Hou MC, Tasi CY*, Huang YH*. Low but Long-lasting Risk of Reversal of Seroconversion in Patients With Rheumatoid Arthritis Receiving Immunosuppressive Therapy. Clin Gastroenterol Hepatol. 2020 Oct;18(11):2573–2581 (*corresponding author)

5. Lee PC, Chao Y, Chen MH, Lan KH, Lee IC, Hou MC, Huang YH*. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J ImmunoTher Cancer 2020 Aug;8(2):e001072 (*corresponding author)

回到最上